Search the GHTC website

Global health R&D delivers for Mississippi

US government investment in global health R&D has delivered

$40.6 million
to Mississippi research institutions
500+ new jobs
for Mississippi
Mississippi's top USG-funded global health R&D institutions

Mississippi's top USG-funded global health R&D institutions

University of Mississippi
$24.1 million
University of Mississippi Medical Center
$12 million
Jackson State University
$1.8 million
Mississippi State University
$1.3 million
University of Southern Mississippi
$930 thousand
Elsohly Laboratories Inc.
$258 thousand
Mississippi University for Women
$201 thousand

Mississippi's top areas of global health R&D by USG funding

Diarrheal diseases
Hepatitis C
Neglected tropical diseases
Kinetoplastid diseases
Reproductive health
Bacterial pneumonia & meningitis
Cryptococcal meningitis
Multi-disease/health area R&D
Global health R&D at work in Mississippi

The University of Mississippi School of Pharmacy is working to make a common malaria drug safer. Primaquine is an inexpensive drug that is highly effective against malaria. However, people with a certain enzyme deficiency can have a life-threatening reaction to the drug. This deficiency is common in regions where malaria is found, so many public health programs are reluctant to use primaquine. If the researchers can understand why this reaction takes place and alter the drug to stop it, it could be used more widely. Malaria infects nearly 250 million people each year, killing more than half a million, most of whom are young children.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: PMI/USAID/Roger Tete